European Hematology Association
June 12-15, 2025

As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Prescribing Information (PI), Summary of Product Characteristics (SmPC), or product information as appropriate in your country. Information is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access.
This is for your background and educational purposes only and may not be altered or further disseminated in any fashion.

Content to be used in accordance with local CPO guidelines

CML

CML

List of Presentations

CML ITP/wAIHA PNH Other Hematology

Asciminib (ASC) shows superior tolerability vs nilotinib (NIL) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Primary endpoint results of the phase (ph) 3b ASC4START trial

Andreas Hochhaus*, Tim Henrik Brümmendorf, Francois-Xavier Mahon, Delphine Rea, David J. Andorsky, Susanne Saussele, Stephen Strickland, Thomas Cluzeau, Francoise Huguet, Jiří Mayer, Viviane Dubruille, DW Kim, Ilina Micheva, Gabrielle Roth Guepin, Virginia Pilipovic, Jacqueline Ryan, Aoife Smyth, Nabil Amirouchene Angelozzi, Ennan Gu, Himanshu Pokhriyal, Philipp Le Coutre

  • Oral presentation #S166
    Coral-2 | Friday, June 13, 2025 | 17:00 – 18:15 CEST

  • Abstract
This presentation will be available once the congress embargo lifts

New pediatric formulation of asciminib in children with chronic myeloid leukemia in chronic phase: Second interim analysis of pharmacokinetics, safety and growth data from the ASC4Kids study

Markus Metzler*, Jessica Pollard, Hiroyuki Shimada, Shruti Kapoor, Matthias Hoch, Vishal Dhamal, Nithya Agrawal, Christine Rosko, Ana Paula Cardoso, Masakatsu Yanagimachi, Ho Joon Im, Nobuko Hijiya

  • Poster presentation #PF596
    Poster Hall | Friday, June 13, 2025 | 18:30 – 19:30 CEST

  • Abstract
This presentation will be available once the congress embargo lifts

ASC4OPT study: High efficacy and favorable tolerability of asciminib once or twice daily in CML patients with suboptimal response, resistance or intolerance of 2 or more tyrosine kinase inhibitors

Andreas Hochhaus*, Philipp Le Coutre, Dragana Milojkovic, Dennis Kim, Soo Min Lim, Carolina Pavlovsky, Thanh Nguyen, Franck Emmanuel Nicolini, Elena Moiraghi, Sebastian Grosicki, Chi Dung Phu, Gabriel Etienne, Fernando Marco de Lucas, Rosa María Ayala Díaz, Massimo Breccia, Charles Chuah, Roberto Abi Rached, Braja Gopal Sahoo, Peter Schuld, Virginia Pilipovic, Carla Maria Boquimpani

  • Poster presentation #PS1593
    Poster Hall | Saturday, June 14, 2025 | 18:30 – 19:30 CEST

  • Abstract
This presentation will be available once the congress embargo lifts

Interim analysis (IA) results from ASC2ESCALATE support asciminib (ASC) as a treatment (Tx) option in chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI)

Ehab Atallah*, David J. Andorsky, Marlise Luskin, Srinivas Tantravahi, Koji Sasaki, James Dugan, Celeste Bremer, Vivian G. Oehler, Joshua Zeidner, Moshe Y. Levy, Camille Abboud, Paul Koller, Bonnie Kiner-Strachan, Habte A. Yimer, Islam Sadek, Daisy Yang, Dram Laine, John Sabo, Amanda Hall, Dheeraj Gianchandani, Michael Mauro, Jorge Cortes

  • Poster presentation #PF595
    Poster Hall | Friday, June 13, 2025 | 18:30 – 19:30 CEST

  • Abstract
This presentation will be available once the congress embargo lifts

Asciminib after one prior tyrosine kinase inhibitor in patients with chronic myeloid leukemia - A physician panel-based chart review study in the United States

Ehab Atallah, Islam Sadek, Dominick Latremouille-Viau, Carmine Rossi, Andrea Damon, Daisy Yang, Remi Bellefleur, Annie Guerin, David Wei*

  • Poster presentation #PF597
    Poster Hall | Friday, June 13, 2025 | 18:30 – 19:30 CEST

  • Abstract
This presentation will be available once the congress embargo lifts

Improved patient-reported outcomes (PROs) with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST wk 48 analysis

Andreas Hochhaus*, Timothy Hughes, Ghayas Issa, Richard Larson, Felice Bombaci, Jianxiang Wang, DW Kim, Dennis Kim, Jiří Mayer, Yeow Tee Goh, Philipp Le Coutre, Inho Kim, Gabriel Etienne, Shruti Kapoor, Tracey McCulloch, Kamel Malek, Denise DAlessio, Lillian Yau, Naoto Takahashi, Jorge Cortes

  • Poster presentation #PS1588
    Poster Hall | Saturday, June 14, 2025 | 18:30 – 19:30 CEST

  • Abstract
This presentation will be available once the congress embargo lifts

Exploratory analysis of prevalent additional genomic alterations (AGAs) at baseline (BL) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) from ASC4FIRST

Susan Branford, Jorge Cortes, Naoto Takahashi, Richard Larson, Ghayas Issa, Felice Bombaci, Jianxiang Wang, DW Kim, Dennis Kim, Jiří Mayer, Yeow Tee Goh, Philipp Le Coutre, Inho Kim, Gabriel Etienne, Shruti Kapoor, Rajendra Jinwal, Kamel Malek, Amila Sarac, Andreas Bruederle, Pablo Serrano-Fernández, Andreas Hochhaus, Timothy Hughes*

  • Poster presentation #PF593
    Poster Hall | Friday, June 13, 2025 | 18:30 – 19:30 CEST

  • Abstract
This presentation will be available once the congress embargo lifts

The strategy of asciminib management in chronic myeloid leukemia (CML) patients in transplant practice

Yulia Vlasova*, Elena Morozova, Elza Lomaia, Anna Turkina, Ekaterina Chelysheva, Elena Kuzmina, Anna Petrova, Larisa Kuzmina, Tamara Chitanava, Nikita Volkov, Ksenia Tsvirko, Tatiana Rudakova, Ksenia Muslimova, Tatiana Gindina, Dmitriy Motorin, Julia Alexeeva, Valeria Katerina, Ivan Moiseev, Alexander Kulagin

  • Poster presentation #PF594
    Poster Hall | Friday, June 13, 2025 | 18:30 – 19:30 CEST
    Please note that this poster is unavailable since this is an Investigator Initiated Trial (IIT)

  • Abstract
This presentation will be available once the congress embargo lifts

Updated results of Managed-Access Program (MAP) of asciminib use in chronic myeloid leukemia patients in 3 clinical centers

Ekaterina Chelysheva*, Elena Kuzmina, Oleg Shukhov, Elza Lomaia, Elena Morozova, Anna Petrova, Tamara Chitanava, Yulia Vlasova, Evgeniya Sbityakova, Natalia Lazorko, Irina Nemchenko, Anastasia Bykova, Alina Kohno, Anna Turkina

  • Poster presentation #PS1594
    Poster Hall | Saturday, June 14, 2025 | 18:30 – 19:30 CEST
    Please note that this poster is unavailable since this is an Investigator Initiated Trial (IIT)

  • Abstract
This presentation will be available once the congress embargo lifts

Assessment of drug-drug interaction potential between asciminib and atorvastatin in healthy participants

Matthias Hoch, Wendy Weis, Seshulatha Jamalapuram, Michelle Quinlan, Amarnath Bandaru, S. Eralp Bellibas, Asmae Mirkou, Shruti Kapoor, Shefali Kakar

This presentation will be available once the congress embargo lifts

ASC4REAL: Harnessing AI to reveal real-world insights on asciminib efficacy in pre- and post-ponatinib treated CML patients

Anchit Khanna, Hannah Small, Dhamend Lutchman, Bahar Miraghazadeh, Rafael Erlich, Lynette Chee

This presentation will be available once the congress embargo lifts

Impact of adverse events on quality of life in chronic myeloid leukemia (CML) – Results from the patient survey on humanistic burden of intolerance to first or second TKIs (SHIFT) study in the US

Kelly Schoenbeck, Joannie Clements, Karen DeMairo, Jennifer Hiller, David Wei*, Nisha Hazra, Cristina Constantinescu, Yan Meng, Dominick Latremouille-Viau, Gabriel Marquez, Daisy Yang, Andrea Damon, Islam Sadek, Annie Guerin, Kathryn Flynn

  • Poster presentation #PS1595
    Poster Hall | Saturday, June 14, 2025 | 18:30 – 19:30 CEST

  • Abstract
This presentation will be available once the congress embargo lifts

Quality of life and work impacts among caregivers of patients with chronic myeloid leukemia (CML) - A caregiver survey in the US

Kathryn Flynn, Joannie Clements, Karen DeMairo, Jennifer Hiller, David Wei*, Nisha Hazra, Cristina Constantinescu, Yan Meng, Dominick Latremouille-Viau, Gabriel Marquez, Daisy Yang, Andrea Damon, Islam Sadek, Annie Guerin, Kelly Schoenbeck

  • Poster presentation #PS2286
    Poster Hall | Saturday, June 14, 2025 | 18:30 – 19:30 CEST

  • Abstract
This presentation will be available once the congress embargo lifts

Patient-physician communication regarding TKI-related adverse events and their impact on quality of life in CML - Insights from patient and physician surveys in the US

Kathryn Flynn, Kelly Schoenbeck, Karen DeMairo, Joannie Clements, Jennifer Hiller, Nisha Hazra, Cristina Constantinescu, Yan Meng, Dominick Latremouille-Viau, Gabriel Marquez, Daisy Yang, Andrea Damon, Islam Sadek, Annie Guerin, David Wei*

  • Poster presentation #PS2283
    Poster Hall | Saturday, June 14, 2025 | 18:30 – 19:30 CEST

  • Abstract
This presentation will be available once the congress embargo lifts

Real-world treatment patterns of tyrosine kinase inhibitors in Korean patients with chronic myelogenous leukemia

Song Baik, YoungIm Kim, Sung-Eun Lee

This presentation will be available once the congress embargo lifts
View list of select presentations for this compound